Home-Injected MS drug shows promise in chinese patients
NCT ID NCT05199571
Summary
This study tested how well and how safe the drug ofatumumab was for adults in China with relapsing multiple sclerosis (RMS). All 99 participants received the drug as a monthly injection they could give themselves at home after initial clinic visits. Researchers tracked how often participants had symptom flare-ups (relapses) and monitored their brain scans for changes over 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Lanzhou, Gansu, 730030, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510630, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050000, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150001, China
-
Novartis Investigative Site
Wuhan, Hubei, 430030, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110011, China
-
Novartis Investigative Site
Taiyuan, Shanxi, 030001, China
-
Novartis Investigative Site
Ürümqi, Xinjiang, 830054, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Beijing, 065001, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Guangzhou, 510260, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shenzhen, 518036, China
-
Novartis Investigative Site
Tianjin, 300052, China
Conditions
Explore the condition pages connected to this study.